PDCD1 and non-small cell lung carcinoma: Similar data were obtained in patients with non-small cell lung cancer who received anti-PD-1/PD-L1 therapy and with patients with metastatic urothelial cancer treated with immune checkpoint blockade therapy (Figures 9B, C).